Sandoz Receives European Commission Approval for Ondibta Insulin Glargine

Reuters01-14

Sandoz Receives European Commission Approval for Ondibta Insulin Glargine

Sandoz Group AG has received marketing authorization from the European Commission for Ondibta® (insulin glargine), a biosimilar developed and registered by Gan & Lee Pharmaceuticals. Ondibta® is approved for the treatment of diabetes mellitus in adults, adolescents, and children aged two years and above, with demonstrated equivalence to the reference medicine, Lantus® SoloStar®, in terms of safety, quality, and efficacy. The product is expected to launch by early 2027, with the potential to expand access to insulin treatment options for patients across Europe. Under a commercialization agreement, Sandoz will market Ondibta® in Europe and other key territories, while Gan & Lee is responsible for development, registration, manufacturing, and supply.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sandoz Group AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2259272_en), on January 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603988697?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603988697","market":"nz","top_or_hot":-1,"title":"Sandoz Receives European Commission Approval for Ondibta Insulin Glargine","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sandoz Receives European Commission Approval for Ondibta Insulin Glargine\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SDZNY\">Sandoz Group AG</a> has received marketing authorization from the European Commission for Ondibta® (insulin glargine), a biosimilar developed and registered by Gan &amp; Lee Pharmaceuticals. Ondibta® is approved for the treatment of diabetes mellitus in adults, adolescents, and children aged two years and above, with demonstrated equivalence to the reference medicine, Lantus® SoloStar®, in terms of safety, quality, and efficacy. The product is expected to launch by early 2027, with the potential to expand access to insulin treatment options for patients across Europe. Under a commercialization agreement, Sandoz will market Ondibta® in Europe and other key territories, while Gan &amp; Lee is responsible for development, registration, manufacturing, and supply.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SDZXF\">Sandoz Group AG</a> published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2259272_en), on January 14, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sandoz Receives European Commission Approval for Ondibta Insulin Glargine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSandoz Receives European Commission Approval for Ondibta Insulin Glargine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-14 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sandoz Receives European Commission Approval for Ondibta Insulin Glargine\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SDZNY\">Sandoz Group AG</a> has received marketing authorization from the European Commission for Ondibta® (insulin glargine), a biosimilar developed and registered by Gan &amp; Lee Pharmaceuticals. Ondibta® is approved for the treatment of diabetes mellitus in adults, adolescents, and children aged two years and above, with demonstrated equivalence to the reference medicine, Lantus® SoloStar®, in terms of safety, quality, and efficacy. The product is expected to launch by early 2027, with the potential to expand access to insulin treatment options for patients across Europe. Under a commercialization agreement, Sandoz will market Ondibta® in Europe and other key territories, while Gan &amp; Lee is responsible for development, registration, manufacturing, and supply.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SDZXF\">Sandoz Group AG</a> published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2259272_en), on January 14, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL7dszyy:1","article_id":"2603988697","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603988697","pubTimestamp":1768388513,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sandoz Group AG has received marketing authorization from the European Commission for Ondibta , a biosimilar developed and registered by Gan & Lee Pharmaceuticals. Ondibta is approved for the treatment of diabetes mellitus in adults, adolescents, and children aged two years and above, with demonstrated equivalence to the reference medicine, Lantus SoloStar, in terms of safety, quality, and efficacy. The product is expected to launch by early 2027, with the potential to expand access to insulin treatment options for patients across Europe. Under a commercialization agreement, Sandoz will market Ondibta in Europe and other key territories, while Gan & Lee is responsible for development, registration, manufacturing, and supply.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"603087":"甘李药业","BK0239":"医药制造"},"translate_title":"山德士Ondibta甘精胰岛素获得欧盟委员会批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603087":0.9},"content_text":"Sandoz Receives European Commission Approval for Ondibta Insulin Glargine\n    \n\nSandoz Group AG has received marketing authorization from the European Commission for Ondibta® (insulin glargine), a biosimilar developed and registered by Gan & Lee Pharmaceuticals. Ondibta® is approved for the treatment of diabetes mellitus in adults, adolescents, and children aged two years and above, with demonstrated equivalence to the reference medicine, Lantus® SoloStar®, in terms of safety, quality, and efficacy. The product is expected to launch by early 2027, with the potential to expand access to insulin treatment options for patients across Europe. Under a commercialization agreement, Sandoz will market Ondibta® in Europe and other key territories, while Gan & Lee is responsible for development, registration, manufacturing, and supply.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sandoz Group AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2259272_en), on January 14, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603988697","isCrawlerRequest":true}